

## Supplementary Materials for







### **Ciliation of muscle stem cells is critical to maintain regenerative capacity and is lost during aging**

**Adelaida R. Palla<sup>1†</sup>, Keren I. Hilgendorf<sup>2,3†</sup>, Ann V. Yang<sup>1</sup>, Jaclyn P. Kerr<sup>4</sup>, Aaron C. Hinken<sup>4</sup>, Janos Demeter<sup>2</sup>, Peggy Kraft<sup>1</sup>, Nancie A. Mooney<sup>2</sup>, Nora Yucel<sup>1</sup>, David M. Burns<sup>1</sup>, Yu Xin Wang<sup>1</sup>, Peter K. Jackson<sup>2, 5\*</sup> and Helen M. Blau<sup>1\*</sup>**

Correspondence to: [hblau@stanford.edu](mailto:hblau@stanford.edu), [pjackson@stanford.edu](mailto:pjackson@stanford.edu)








**This PDF file includes:**

Supplementary Figures 1-5




## Supplementary Figure 1. Loss of cilia in MuSCs impairs muscle regeneration and strength recovery

**(a)** Myofibers were isolated from *Extensor digitorum longus* (EDL) muscles from transgenic CENTRIN2-GFP, ARL13B-mCherry mice. PAX7 staining was performed to identify MuSCs. All cells have a centrosome (CENTRIN2-GFP<sup>+</sup>) and ciliated cells are also ARL13B-mCherry<sup>+</sup>. Pink arrowhead indicates the primary cilium on the surface of MuSCs. Scale bars: 10  $\mu$ M. **(b)** Pax7-specific Ift88 conditional knockout mice ( $Pax7^{CreERT2};IFT88^{-/-}$ , IFT88<sup>-/-</sup>), heterozygous mice ( $Pax7^{CreERT2};IFT88^{+/f}$ , IFT88<sup>+/+</sup>) or control littermates ( $Pax7^{CreERT2};IFT88^{+/+}$ , control) were treated with tamoxifen (TAM) at 8 weeks of age. Myofibers were isolated and stained for PAX7, FOP and IFT88. Percent of IFT88<sup>+</sup> cilia on Pax7<sup>+</sup> MuSCs was quantified (n=39 control, n=32 IFT88<sup>+/+</sup> and n=23 IFT88<sup>-/-</sup> myofibers were analyzed). **(c)** Percent of short (<1  $\mu$ M) and long (>1  $\mu$ M) cilia on Pax7<sup>+</sup> MuSCs quantified from isolated myofibers of control, IFT88<sup>+/+</sup> and IFT88<sup>-/-</sup> mice (n=75 control, 79 IFT88<sup>+/+</sup>, 81 IFT88<sup>-/-</sup> total myofibers were analyzed from 3 control and 4 IFT88<sup>+/+</sup> and IFT88<sup>-/-</sup> independent mice; average percent of ciliated MuSCs per mouse is shown). Individual replicates of Fig. 1c. **(d)** Force-frequency curves of control, IFT88<sup>+/+</sup> and IFT88<sup>-/-</sup> mice 2 weeks post-injury. **(e)** Plantar flexion tetanic isometric force of control, IFT88<sup>+/+</sup> and IFT88<sup>-/-</sup> mice on day 14 post-injury (absolute levels). **(f)** Gastrocnemius muscle mass 2 weeks post-injury. \*P<0.05, \*\*P<0.01, \*\*\*P<0.001. ANOVA test with Fisher's LSD for multiple comparisons (**c-f**). Source data are provided as a Source Data file. Means+s.e.m. n.s., non-significant.

**a****b****c****d****e****f**





## Supplementary Figure 2. Transcriptome analysis of control and IFT88<sup>-/-</sup> MuSCs

**(a)** Heat map of differentially expressed genes ( $p < 0.1$ ) between control or IFT88<sup>-/-</sup> MuSCs freshly isolated from hindlimb muscles. **(b)** Enriched canonical pathways of the differentially expressed genes in IFT88<sup>-/-</sup> MuSCs indicated by Ingenuity Pathway Analysis (IPA). **(c)** Proliferation of MuSCs electroporated with siRNA targeting ciliary genes *Kif3a*, *Cep164* or control (scrambled, scr), shown as fold change normalized to scr ( $n=4$  independent mice averaged with 3 technical replicates each). **(d)** Gene expression levels of *Cep164* and *Kif3a* with siRNA targeting ciliary genes *Kif3a*, *Cep164* or control (scrambled, scr) ( $n=3$ ). **(e)** Left: Representative images of cultured control and IFT88<sup>-/-</sup> MuSCs after 7 days on collagen-coated plates showing MyHC immunostaining. Scale bars: 50  $\mu$ M. Right: Quantification of MyHC positive control and IFT88<sup>-/-</sup> differentiated MuSCs ( $n=7$  mice per genotype). **(f)** Individual replicates of Fig. 2a. Engraftment of GFP/luc-labeled control and IFT88<sup>-/-</sup> MuSCs. Bioluminescence imaging (BLI) signal post-transplant expressed as average radiance ( $\text{p s}^{-1} \text{ cm}^{-2} \text{ sr}^{-1}$ ) ( $n=5$  replicates per condition). ANOVA test with Fisher's LSD for multiple comparisons **(c,d,f)**; Mann Whitney test **(e)**. \* $P < 0.05$ . Source data are provided as a Source Data file. Means+s.e.m. n.s., non-significant.



### Supplementary Figure 3. SMO agonist treatment promotes MuSC expansion


Individual replicates of Fig. 3f. Expansion of endogenous MuSCs in Pax7<sup>CreERT2</sup>;Rosa26-LSL-Luc mice treated with tamoxifen (TAM) to label resting MuSCs and assayed by bioluminescence imaging (BLI) post-notexin injury. BLI signal was normalized to day 3 post-injury prior to vehicle or SAG1.3 injection (n = 8 mice per condition). \*\*P<0.01, \*\*\*P<0.001. ANOVA test with Fisher's LSD for multiple comparisons. Source data are provided as a Source Data file. Means±s.e.m. n.s., non-significant.



#### **Supplementary Figure 4. Aged MuSCs present decreased ciliation and Hedgehog signaling**

**(a)** Representative confocal images of uninjured/resting *Extensor digitorum longus* (EDL) myofibers of young (2 months) and aged (>24 months) C57BL/6 wild-type (wt) mice showing cilia immunostaining in Pax7<sup>+</sup> MuSCs. Scale bars: 10  $\mu$ m. DAPI, blue; PAX7, white; FOP, green; detyrosinated tubulin, red. **(b)** Percent of short (<1  $\mu$ M) and long (>1  $\mu$ M) cilia on Pax7<sup>+</sup> MuSCs quantified isolated myofibers from young and aged myofibers (n=58 myofibers total per age group isolated from n=4 young and n=5 aged mice, average percent of ciliated MuSCs per mouse is shown). **(c)** Individual replicates for Fig. 4e. Expression of *Ptch1* after *Tibialis anterior* muscle injury. n=3-7 mice per timepoint. **(d)** Individual replicates for Fig. 4f. Expression of *Gli2* after *Tibialis anterior* muscle injury. n=3-7 mice per timepoint. ANOVA test with Fisher's LSD for multiple comparisons **(b-d)**. \*P<0.05, \*\*P<0.01, \*\*\*P<0.001 \*\*\*\*P<0.0001. Source data are provided as a Source Data file. Mean + SEM. n.s., non-significant.





### Supplementary Figure 5. Muscle Stem Cell Sorting Strategy

Compensation was performed due to overlap between APC and APC-Cy7. SSC and FSC were gated for small cells. Cells were gated for DAPI negative, Lin-APC-Cy7 negative (CD31, SCA1, CD45, CD11B), a7-PE positive, and CD34-APC positive.